These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
229 related articles for article (PubMed ID: 24260029)
1. When to start antiretroviral therapy in children aged 2-5 years: a collaborative causal modelling analysis of cohort studies from southern Africa. Schomaker M; Egger M; Ndirangu J; Phiri S; Moultrie H; Technau K; Cox V; Giddy J; Chimbetete C; Wood R; Gsponer T; Bolton Moore C; Rabie H; Eley B; Muhe L; Penazzato M; Essajee S; Keiser O; Davies MA; PLoS Med; 2013 Nov; 10(11):e1001555. PubMed ID: 24260029 [TBL] [Abstract][Full Text] [Related]
2. Growth and Mortality Outcomes for Different Antiretroviral Therapy Initiation Criteria in Children Ages 1-5 Years: A Causal Modeling Analysis. Schomaker M; Davies MA; Malateste K; Renner L; Sawry S; N'Gbeche S; Technau KG; Eboua F; Tanser F; Sygnaté-Sy H; Phiri S; Amorissani-Folquet M; Cox V; Koueta F; Chimbete C; Lawson-Evi A; Giddy J; Amani-Bosse C; Wood R; Egger M; Leroy V; Epidemiology; 2016 Mar; 27(2):237-46. PubMed ID: 26479876 [TBL] [Abstract][Full Text] [Related]
3. Optimal timing of antiretroviral treatment initiation in HIV-positive children and adolescents: a multiregional analysis from Southern Africa, West Africa and Europe. Schomaker M; Leroy V; Wolfs T; Technau KG; Renner L; Judd A; Sawry S; Amorissani-Folquet M; Noguera-Julian A; Tanser F; Eboua F; Navarro ML; Chimbetete C; Amani-Bosse C; Warszawski J; Phiri S; N'Gbeche S; Cox V; Koueta F; Giddy J; Sygnaté-Sy H; Raben D; Chêne G; Davies MA; Int J Epidemiol; 2017 Apr; 46(2):453-465. PubMed ID: 27342220 [TBL] [Abstract][Full Text] [Related]
4. Predicting patterns of long-term CD4 reconstitution in HIV-infected children starting antiretroviral therapy in sub-Saharan Africa: a cohort-based modelling study. Picat MQ; Lewis J; Musiime V; Prendergast A; Nathoo K; Kekitiinwa A; Nahirya Ntege P; Gibb DM; Thiebaut R; Walker AS; Klein N; Callard R; PLoS Med; 2013 Oct; 10(10):e1001542. PubMed ID: 24204216 [TBL] [Abstract][Full Text] [Related]
5. Time-varying age- and CD4-stratified rates of mortality and WHO stage 3 and stage 4 events in children, adolescents and youth 0 to 24 years living with perinatally acquired HIV, before and after antiretroviral therapy initiation in the paediatric IeDEA Global Cohort Consortium. Desmonde S; Neilan AM; Musick B; Patten G; Chokephaibulkit K; Edmonds A; Duda SN; Malateste K; Wools-Kaloustian K; Ciaranello AL; Davies MA; Leroy V; J Int AIDS Soc; 2020 Oct; 23(10):e25617. PubMed ID: 33034417 [TBL] [Abstract][Full Text] [Related]
6. Optimal time for initiating antiretroviral therapy (ART) in HIV-infected, treatment-naive children aged 2 to 5 years old. Siegfried N; Davies MA; Penazzato M; Muhe LM; Egger M Cochrane Database Syst Rev; 2013 Oct; 10(10):CD010309. PubMed ID: 24114324 [TBL] [Abstract][Full Text] [Related]
7. Temporal trends in the characteristics of children at antiretroviral therapy initiation in southern Africa: the IeDEA-SA Collaboration. Davies MA; Phiri S; Wood R; Wellington M; Cox V; Bolton-Moore C; Timmerman V; Moultrie H; Ndirangu J; Rabie H; Technau K; Giddy J; Maxwell N; Boulle A; Keiser O; Egger M; Eley B; PLoS One; 2013; 8(12):e81037. PubMed ID: 24363808 [TBL] [Abstract][Full Text] [Related]
8. Global temporal changes in the proportion of children with advanced disease at the start of combination antiretroviral therapy in an era of changing criteria for treatment initiation. Panayidou K; Davies MA; Anderegg N; Egger M; J Int AIDS Soc; 2018 Nov; 21(11):e25200. PubMed ID: 30614622 [TBL] [Abstract][Full Text] [Related]
9. Optimal time for initiation of antiretroviral therapy in asymptomatic, HIV-infected, treatment-naive adults. Siegfried N; Uthman OA; Rutherford GW Cochrane Database Syst Rev; 2010 Mar; 2010(3):CD008272. PubMed ID: 20238364 [TBL] [Abstract][Full Text] [Related]
10. Gender differences in survival among adult patients starting antiretroviral therapy in South Africa: a multicentre cohort study. Cornell M; Schomaker M; Garone DB; Giddy J; Hoffmann CJ; Lessells R; Maskew M; Prozesky H; Wood R; Johnson LF; Egger M; Boulle A; Myer L; PLoS Med; 2012; 9(9):e1001304. PubMed ID: 22973181 [TBL] [Abstract][Full Text] [Related]
11. Life expectancies of South African adults starting antiretroviral treatment: collaborative analysis of cohort studies. Johnson LF; Mossong J; Dorrington RE; Schomaker M; Hoffmann CJ; Keiser O; Fox MP; Wood R; Prozesky H; Giddy J; Garone DB; Cornell M; Egger M; Boulle A; PLoS Med; 2013; 10(4):e1001418. PubMed ID: 23585736 [TBL] [Abstract][Full Text] [Related]
12. When to start antiretroviral therapy in resource-limited settings. Walensky RP; Wolf LL; Wood R; Fofana MO; Freedberg KA; Martinson NA; Paltiel AD; Anglaret X; Weinstein MC; Losina E; Ann Intern Med; 2009 Aug; 151(3):157-66. PubMed ID: 19620143 [TBL] [Abstract][Full Text] [Related]
13. Earlier Antiretroviral Therapy Initiation and Decreasing Mortality Among HIV-infected Infants Initiating Antiretroviral Therapy Within 3 Months of Age in South Africa, 2006-2017. Iyun V; Technau KG; Eley B; Rabie H; Boulle A; Fatti G; Egger M; Tanser F; Wood R; Fairlie L; Cotton MF; Davies MA Pediatr Infect Dis J; 2020 Feb; 39(2):127-133. PubMed ID: 31725119 [TBL] [Abstract][Full Text] [Related]
14. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. ; Sterne JA; May M; Costagliola D; de Wolf F; Phillips AN; Harris R; Funk MJ; Geskus RB; Gill J; Dabis F; Miró JM; Justice AC; Ledergerber B; Fätkenheuer G; Hogg RS; Monforte AD; Saag M; Smith C; Staszewski S; Egger M; Cole SR Lancet; 2009 Apr; 373(9672):1352-63. PubMed ID: 19361855 [TBL] [Abstract][Full Text] [Related]
15. Access to antiretroviral therapy in HIV-infected children aged 0-19 years in the International Epidemiology Databases to Evaluate AIDS (IeDEA) Global Cohort Consortium, 2004-2015: A prospective cohort study. Desmonde S; Tanser F; Vreeman R; Takassi E; Edmonds A; Lumbiganon P; Pinto J; Malateste K; McGowan C; Kariminia A; Yotebieng M; Dicko F; Yiannoutsos C; Mubiana-Mbewe M; Wools-Kaloustian K; Davies MA; Leroy V; PLoS Med; 2018 May; 15(5):e1002565. PubMed ID: 29727458 [TBL] [Abstract][Full Text] [Related]
16. Mortality in patients with HIV-1 infection starting antiretroviral therapy in South Africa, Europe, or North America: a collaborative analysis of prospective studies. Boulle A; Schomaker M; May MT; Hogg RS; Shepherd BE; Monge S; Keiser O; Lampe FC; Giddy J; Ndirangu J; Garone D; Fox M; Ingle SM; Reiss P; Dabis F; Costagliola D; Castagna A; Ehren K; Campbell C; Gill MJ; Saag M; Justice AC; Guest J; Crane HM; Egger M; Sterne JA PLoS Med; 2014 Sep; 11(9):e1001718. PubMed ID: 25203931 [TBL] [Abstract][Full Text] [Related]
17. Monitoring and switching of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa: collaborative analysis. Haas AD; Keiser O; Balestre E; Brown S; Bissagnene E; Chimbetete C; Dabis F; Davies MA; Hoffmann CJ; Oyaro P; Parkes-Ratanshi R; Reynolds SJ; Sikazwe I; Wools-Kaloustian K; Zannou DM; Wandeler G; Egger M; Lancet HIV; 2015 Jul; 2(7):e271-8. PubMed ID: 26423252 [TBL] [Abstract][Full Text] [Related]
18. Early mortality and loss to follow-up in HIV-infected children starting antiretroviral therapy in Southern Africa. Fenner L; Brinkhof MW; Keiser O; Weigel R; Cornell M; Moultrie H; Prozesky H; Technau K; Eley B; Vaz P; Pascoe M; Giddy J; Van Cutsem G; Wood R; Egger M; Davies MA; J Acquir Immune Defic Syndr; 2010 Aug; 54(5):524-32. PubMed ID: 20588185 [TBL] [Abstract][Full Text] [Related]
19. HIV treatment eligibility expansion and timely antiretroviral treatment initiation following enrollment in HIV care: A metaregression analysis of programmatic data from 22 countries. Tymejczyk O; Brazier E; Yiannoutsos C; Wools-Kaloustian K; Althoff K; Crabtree-Ramírez B; Van Nguyen K; Zaniewski E; Dabis F; Sinayobye JD; Anderegg N; Ford N; Wikramanayake R; Nash D; PLoS Med; 2018 Mar; 15(3):e1002534. PubMed ID: 29570723 [TBL] [Abstract][Full Text] [Related]
20. Discordance between CD4 cell count and CD4 cell percentage: implications for when to start antiretroviral therapy in HIV-1 infected children. ; Boyd K; Dunn DT; Castro H; Gibb DM; Duong T; Aboulker JP; Bulterys M; Cortina-Borja M; Gabiano C; Galli L; Giaquinto C; Harris DR; HugheS M; McKinney R; Mofenson L; Moye J; Newell ML; Pahwa S; Palumbo P; Rudin C; Sharland M; Shearer W; Thompson B; Tookey P AIDS; 2010 May; 24(8):1213-7. PubMed ID: 20386428 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]